Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylotarg Phase IV Study In AML To Examine Combo Therapy For First-line Use

Executive Summary

Wyeth-Ayerst is planning a Phase IV study to evaluate Mylotarg in combination therapy for the treatment of patients recently diagnosed with CD33 positive acute myeloid leukemia, the company said.

You may also be interested in...



Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed

Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee

Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed

Accelerated approval Phase IV commitments for seven oncologic products will be reviewed at the March 12-13 meeting of FDA's Oncologic Drugs Advisory Committee

Wyeth Mylotarg Safety Profile Supports Use In Patients 60 - Advisory Cmte.

Wyeth's treatment for relapsed acute myeloid leukemia patients Mylotarg was recommended for accelerated approval in patients 60 years and older by FDA's Oncologic Drugs Advisory Committee March 17.

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel